Description
What is Semaglutide 30mg?
Semaglutide is a GLP-1R agonist with 94% sequence homology to native GLP-1, acylated for extended half-life (~7 days). The 30mg/vial format provides a high-dose configuration for research protocols requiring elevated single-dose concentrations or reduced reconstitution frequency. GLP-1R activation suppresses appetite via hypothalamic pathways, delays gastric emptying, and stimulates glucose-dependent insulin secretion. SUSTAIN and STEP program Phase 3 data: 15-17% mean weight reduction. The 30mg format is suited for sustained high-dose protocols, stock preparation for high-throughput research, and studies at concentrations above standard 10-20mg formats.
Reviews
There are no reviews yet.